Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.33 --0%
Revenue Growth %: -49.8%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
CRMT, FOMI, FLES, More
Revenue Growth %: -49.8%
Financial Fact:
REVENUES: 4.67M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.05), versus ($0.07) reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Regional Director in US Adjusts List of Top Names
- Evercore ISI on ServiceNow (NOW): 'Thoughts Into F2Q & Takeaways From Quarterly Partner Survey'
- Wells Fargo Lists 8 Tactical Ideas for Q3 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
